Here’s a full, no-fluff breakdown for BBAI, including live price, latest news, analyst outlook, technicals, and a wheel-suitable options plan:

---

📊 Live Quote

• Price: $7.44
• Today’s Range: $7.04–$8.17, supported by multi-million share volume (The Economic Times, StockAnalysis)

---

📄 News & Analyst Snapshot

• YTD Performance: +82%, riding strong momentum in AI/defense sectors (The Economic Times)
• Analyst Ratings: Moderate Buy consensus (2 Buys, 2 Holds) (MarketBeat)
• Price Targets:
  • Average: ~$5.80–6.33 → implying ~15–25% downside (MarketBeat, TradingView, Zacks)
  • Highs: $9 (bull case), Lows: $3.50 (bear case) (StockAnalysis)
• Company Updates: Q2 earnings scheduled for Aug 11; new partnerships in UAE, biometrics, and military AI (BigBear.ai Holdings, Inc.)

---

📉 Chart & Risk Snapshot

• Strong breakout on heavy volume — analysts flag “Strong Buy” on momentum (MarketBeat)
• Support cluster: $7.30–7.60; overhead resistance ~ $8.50–9.00 (The Economic Times, BigBear.ai Holdings, Inc.)
• Risks: Low revenue ($159M), operating loss (–$38M), cash burn; analyst average target below current price – moderate caution (MarketWatch)

---

✅ Scorecard (1–10)

• Financial Health: 5 — cash-rich but unprofitable
• Growth Potential: 7 — defense/AI tailwinds
• Volatility & Premiums: 8 — high IV = juicy premium
• Technical Setup: 7 — breakout confirmed, support intact
• Total Score: 6.8/10 — Slightly below core threshold (7), but strong for managed wheel

---

🧭 Recommended Options Strategy

🔁 Sell PUT (to enter position)

• Strike: $7.00 (OTM)—key support edge
• DTE: 35–45 days (targeting Sept expiry)
• Estimated Premium: $1.00–$1.20 (15–17% ROC) — check live chain
• Breakeven: $6.00–$6.20 — well below support
• POP: ~55–60%; moderate chance of assignment

♻️ If Assigned: Begin Covered Call Cycle

• Strike: $8.00–8.50 OTM
• DTE: 30–45 days
• Goal: Lock in ongoing premium, capitalize if breakout holds

⚠️ Risk Management

• Set alert at $7.30 — consider rolling or closing if it fails
• Watch earnings release on Aug 11 — could create volatility

---

🔍 Summary

You’re getting premium, potential assignment below support, and a structured path to repeated income via covered calls. Analyst sentiment is cautious, but technicals and momentum support this trade. If you’re comfortable with moderate biotech-style risk, this is a solid wheel opportunity.

Would you like me to pull live quotes for the $7 put (ROC, IV, POP) and for the corresponding covered call leg?